Regenerative Medicine Exhibit Sponsorship Opportunity

AAPM&R is hosting Regenerative Medicine: Promises and Challenges in the Treatment of Musculoskeletal Conditions, a one-day didactic preconference course designed to address the advances in regenerative medicine for Physiatrists. Expand your access to this audience!

Regenerative Medicine: Promises and Challenges in the Treatment of Musculoskeletal Conditions

- Wednesday, October 24, 2018, 8 am-5 pm
- Hyatt Regency, Orlando, Florida
- Up to 75 attendees and 8 faculty

Exhibit Sponsorship Includes the Following:

- Table top exhibit near the course
- Acknowledgement as an Exhibit Sponsor on signage to be displayed near the exhibit table
- Acknowledgement as an Exhibit Sponsor at the activity and on the AAPM&R website
- Limited to 3 sponsors

Fee: $2,500

Additional Opportunity:

- Address the attendees for 5-7 minutes
- Opportunity is limited to 2 organizations

Fee: $3,000

Topics Include:

- Regenerative Interventions in Orthopedics and Sports Medicine
- Prolotherapy
- Platelet-rich Plasma (PRP)
- Adipose vs Bone Marrow Derived Stem Cell Therapies
- Orthobiologic Treatments for Spine Pain
- Technical Issues in the Harvesting and Concentrating Stem Cells
- Regulatory Issues in Regenerative Orthopedics-2018 Update

View the course agenda attached!

Contact us to learn about additional opportunities.
www.aapmr.org/about-aapm-r/corporate-support
For more information contact: Sharon Popielewski, (847) 737-6048 or spopielewski@aapmr.org
www.aapmr.org
Regenerative Medicine: Promises and Challenges in the Treatment of Musculoskeletal Conditions
Prathap Jayaram, MD, FAAPMR and Gerry Malanga, MD, FAAPMR (Course Directors)

Wednesday, October 24
8:00 am – 5:00 pm

Regenerative Medicine has been a recent clinical utility in addressing the unmet need in orthopedic injury. There have been significant clinical and basic science advances in technology and delivery strategy in the last few years. This course brings together leading experts to discuss these advances across multiple domains including stem cell derived therapies, autologous blood derived therapies and gene transfer strategies.

8:00 am – 8:30 am  Registration & Breakfast

8:45 am – 9:00 am  Welcome and Opening Remarks
Gerry Malanga, MD, Workshop Course Director
Director-New Jersey Regenerative Institute & Professor Rutgers University/Kessler, Physical Medicine& Rehabilitation

Prathap Jayaram MD, Workshop Course Director
Director of Regenerative Sports Medicine
Assistant Professor of PM& Orthopedic Surgery Baylor College of Medicine

9:05 am – 9:35 am  Rationale for Regenerative Interventions in Orthopedics and Sports Medicine
William Micheo, MD
• Review barriers and limitations of common medications prescribed for tendinopathies and osteoarthritis
• Review toxicity profile of commonly used local anesthetics
• Review of current evidence against the use of corticosteroids for tendon injury, cartilage injury and in lumbar pathology.

9:40 am – 10:25 am  Prolotherapy: Current Status and utility in a Regenerative clinical practice
Joanne Borg-Stein, MD
• Basic overview of Prolotherapy including proposed mechanisms (compare and contrast)
• What is the scientific literature to support these treatments?
• How & When to apply Prolotherapy treatments in practice?

10:30 am – 10:45 am  Break

10:50 am – 11:35 am  Basic Terminology in Regenerative/Stem Cell Therapies: The ABCs of Stem Cell Language
Prathap Jayaram, MD
• What are Mesenchymal stem cells (MSCs)?
• What are the actions/functions of MSCs?
• What are the differences between bone marrow and adipose-derived stem cells?
• Understand the terminologies used in scientific literature regarding stem cells/MSC

11:40 am – 12:25 pm  Platelet-rich Plasma (PRP): Current clinical status and applications
Kenneth Mautner, MD
• What is the evidence of PRP for tendinopathies?
• What is the evidence of PRP for cartilage pathology/OA?
• Where the proper place for PRP in tendinopathies and cartilage pathology?

12:30 pm – 1:00 pm  Panel Discussion/ Q&A

1:00 pm – 1:30 pm  Lunch
1:40 pm – 2:10 pm  Adipose vs Bone Marrow Derived Stem Cell Therapies  
*Gerry Malanga, MD*  
- What is the evidence for/against bone marrow-derived stem cell therapies in orthopedic conditions?  
- What are the concerns in using adipose-derived stem cell therapies in orthopedic conditions?  
- Are adipose-derived stem cells superior or inferior to bone marrow derived stem cells?  
- How a clinician can be compliant using adipose-derived stem cell therapies  
- Update on targeting meniscal tears

2:15 pm – 2:45 pm  Orthobiologic Treatments for Spine Pain  
*Jay Bowen, DO*  
- What are the various proposed biologic agents for spine conditions?  
- What is the evidence for/against PRP for disc; facet; facet and SI joint pathology?  
- What is the evidence for/against stem cell Tx for disc; facet; facet and SI joint pathology?

2:50 pm – 3:20 pm  Technical Issues in the Harvesting and Concentrating Stem Cells (Bone Marrow and Adipose Derived)  
*Jay Bowen, DO*  
- What equipment/staff need to be available?  
- Description of the collection techniques, including anesthesia, sterile field, positioning, potential danger zones, etc.  
- Recommendations for pain/anxiety control  
- Overview of guidance techniques  
- Tips and tricks for obtaining enough aspirate  
- Risks in harvesting and concentrating stem cells

3:20 pm – 3:35 pm  Break

3:40 pm -- 4:10 pm  Regulatory Issues in Regenerative Orthopedics-2018 Update  
*Imran Siddiqui, MD*  
- Understand the FDA position on the use of stem cells/PRP  
- If we are using an FDA approved kit, are we OK?  
- Are there variations from state to state?  
- Are there liability concerns from the use of a non-standard treatment?  
- Is there data to support the safety and clinical efficacy of stem cells for orthopedic conditions?

4:15 pm – 4:45pm  Panel Perspectives/Future Directions: Expert Opinion on the Applications of Various Regenerative Treatments for Orthopedic Conditions  
*All faculty*  
- Dextrose  
- Gene Therapy  
- PRP  
- Bone marrow MSCs  
- Adipose-derived MSCs

4:45 pm  Summary/Conclusions  
*Gerard Malanga, MD*